BUSINESS
Fed policy: Base case is for rate cuts, but the question is when
While the case for soft landing gets stronger, Fed is in no hurry to cut rates
BUSINESS
Syngene: Weak funding environment leads to a soft patch
The research division proves to be a drag while manufacturing turns out to be the saviour
BUSINESS
Laurus Labs: CDMO ramp-up has some runway ahead before it flies
The company’s investment in new-age technologies and talent, which shall pay back in a longer timeframe, is the chief reason to remain invested in it.
BUSINESS
Nova Agritech IPO: Hunting for high growth capital, eyes ‘one-stop solution provider’ tag
The sustainability of margins and the growth trajectory will be key factors to watch
BUSINESS
Aarti Industries: Increasing share of long-term contracts
The company’s existing long-term contracts can potentially generate more than one-third of the revenue it generated in FY23. As new plants and products get commissioned, Aarti would increase the share of longer-term contracts
TRENDS
Discovery Series: New capacity, R&D uptrend to kickstart new earnings cycle for this healthcare proxy
Tarsons Products is well positioned to gain from the surge in R&D investments in new molecules in the labware industry and demand for diagnostic services.
BUSINESS
Aarti Industries: Sequential improvements support investment case
Though long-term contracts have been a mixed bag for the company so far, as and when new plants and products get commissioned, Aarti would increase the share of such contracts.
BUSINESS
Syngene: Preferred CRAMS play for the long term
The company’s underperformance, compared to the Nifty, is not justified, and there is merit in considering the stock at the current levels. In the medium term, complex APIs and biologics manufacturing would be the growth drivers.
BUSINESS
Ami Organics: Multiple growth catalysts taking shape
Ami Organics is making its mark in the niche segments of chemicals having applications in lithium-ion batteries and semiconductors.
BUSINESS
Innova Captab IPO: A pricey contract manufacturer
The prime driver of growth is the volume visibility from contract duration, which is typically in the range of 2-5 years
BUSINESS
Equity strategy: Is a spoiler in the making for the Santa Claus rally?
The emerging Suez trade channel crisis might rekindle inflation fears. Advanced economies are already facing a sharp deceleration in growth indicators
BUSINESS
Fed policy: Dot plot suggests a pivot towards rate cuts
Domestic interest sensitive sectors can have positive rub-off
BUSINESS
Is the time ripe to add position in this chemical stock?
The company stands out due to the contractual nature of some of its businesses despite an adverse demand-supply situation
BUSINESS
Mandatory ACs in trucks: Multiple companies to benefit from the move
With the outlook for commercial vehicles remaining positive, Subros, Amber, SRF, and Navin Flurine will be gainers
BUSINESS
Himadri Speciality: Carbon companies scouting for new growth levers
Announces plan to set up India’s first commercial plant for Lithium Ion Phosphate Cathode Active Material.
BUSINESS
Balaji Amines: How long would destocking continue?
While the company may face pricing pressure in the next few quarters, it continues to target new products under the import substitution strategy. This augurs well for investors
BUSINESS
Equity strategy — How will the market react to state election results?
Improved political stability is a positive factor indeed, but elevated valuations mean they will seek support in earnings momentum even though global volatility lurks in the background
BUSINESS
PCBL: Do the unrelated M&As dampen the investment argument?
The company’s strategy to “future-proof” product profile is sensible but execution is key to the success of this endeavour
BUSINESS
Why are the US Fed and Street having divergent views?
It is prudent for investors to bet on the resilient domestic earnings story
BUSINESS
Concord Biotech: Operating leverage in play; accumulate for the long haul
This leading fermentation play on APIs is a worthy watch, given the scope for a ramp-up in new facilities, foray into injectables and a strong balance sheet.
BUSINESS
Are equities factoring in soft landing? What can go wrong?
Central banks are trying to bring inflation further down and a soft-landing doesn’t look certain as yet
BUSINESS
Galaxy Surfactants: signs of broad-based volume growth
The company exudes confidence on the back of its execution record and its defensive business profile, unlike peers in the chemical industry.
BUSINESS
Ami Organics: Fermion contract raises FY25 earnings visibility
Capex in Ankleshwar, pick-up in supplies for Fermion and a foray into the electro-lyte additive business are the other factors prompting the company to expect a bounce-back in growth in FY25.
BUSINESS
Does Aarti’s result suggest a turnaround for the chemical sector?
While the Indian chemicals industry remains a multi-decade opportunity and Aarti Industries is among the front runners, it faces many challenges in the short run.
